Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems
Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (5) · 549-564
DOI: 10.1111/apt.17309 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, published online on 2022-12-10. Written by Lucy Hocking and 8 co-authors. Institution: RAND Europe, Cambridge, UK. Major MEDLINE topics: Clostridioides difficile, Clostridium Infections. Cited 22 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ferring.
Abstract (original language)
Background
There is growing interest in faecal microbiota transplantation (FMT) as a treatment for recurrent Clostridioides difficile infection (CDI), but evidence on the diverse requirements for safe, effective and accessible services is fragmented and limited.
Aims
To identify key components of FMT provision relating to the patient care pathway, stool donor pathway and wider healthcare system, and to explore variation in practice Methods We conducted a narrative review of the literature and consultations with key clinical experts in the field. Evidence is drawn from high‐income country contexts, with an emphasis on Australia, Canada, Italy and the United Kingdom as case example countries.
Results
We identify and discuss key challenges to do with healthcare capacity (workforce, FMT and stool banking facilities), donors and donations, patient access and choice of FMT delivery routes, regulation, costs and reimbursement. We also identify improvement opportunities to increase awareness of FMT and referral processes, physician training, maintaining patient registries and outcome monitoring metrics, in‐country regulatory harmonisation and tackling reimbursement challenges and discuss future research needs.
Conclusion
Effectively bringing FMT to patients in a healthcare system requires much more than just the existence of a clinically effective procedure. With FMT being a potentially effective treatment option for recurrent CDI for many patients, a well‐rounded understanding of how appropriate FMT capacity can be built and nurtured is important for both healthcare providers and policymakers seeking to improve patient care.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- RAND Europe, Cambridge, UK.
- Gastroenterology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
- Macquarie University Hospital and Concord Hospital, Sydney, Australia.
- University of Birmingham, Birmingham, UK.
- University of Alberta, Edmonton, Alberta, Canada.
ORCID profiles: Lucy Hocking, Gianluca Ianiro, Rupert W Leong, Tariq Iqbal, Dina Kao, Sonja Marjanovic
Funding
- Ferring
Cite
APA
Hocking, L., Ianiro, G., Leong, R. W., Iqbal, T., Kao, D., Cabling, M., Stockwell, S., Romanelli, R. J., & Marjanovic, S. (2023). Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems. Alimentary Pharmacology & Therapeutics, 57(5), 549-564. https://doi.org/10.1111/apt.17309
Vancouver
Hocking L, Ianiro G, Leong RW, Iqbal T, Kao D, Cabling M, et al. Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems. Alimentary Pharmacology & Therapeutics. 2023;57(5):549-564. doi:10.1111/apt.17309
BibTeX
@article{Hocking2023,
author = {Hocking, Lucy and Ianiro, Gianluca and Leong, Rupert W and Iqbal, Tariq and Kao, Dina and Cabling, Mark and Stockwell, Stephanie and Romanelli, Robert J and Marjanovic, Sonja},
title = {Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {5},
pages = {549--564},
doi = {10.1111/apt.17309}
}
EUVIMED